Management of uterine bleeding during hematopoietic stem cell transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23344397.
- Also identified by DOI 10.1097/aog.0b013e318270ecd3 and PMC identifier 3798064.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hematopoietic stem cell transplant is an effective treatment strategy for a variety of hematologic disorders, but patients are at risk for dysfunctional coagulation and abnormal bleeding. Gynecologists are often consulted before transplant for management of abnormal uterine bleeding, which may be particularly challenging in this context. A premenopausal woman with MonoMAC (a rare adult-onset immunodeficiency syndrome characterized by monocytopenia and Mycobacterium avium complex infections resulting from mutations in GATA2, a crucial gene in early hematopoiesis) presented with pancytopenia, evolving leukemia, and recent strokes, necessitating anticoagulation. During preparation for hematopoietic stem cell transplant, she experienced prolonged menorrhagia requiring transfusions. Surgical therapy was contraindicated, and medical management was successful only when combined with balloon tamponade. Balloon tamponade may be a potentially life-saving adjunct to medical therapy for control of uterine hemorrhage before hematopoietic stem cell transplant.
Medical subject headings
- Estrogens
- Hematopoietic Stem Cell Transplantation
- Induction Chemotherapy
- Leuprolide
- Medroxyprogesterone
- Menorrhagia
- Uterine Balloon Tamponade